KG

Keno Gutierrez

General Partner at BioGeneration Ventures

Amsterdam, North Holland

Overview

Work Experience

  • General Partner

    2021 - Current

  • Chairman of the Board

    2022

    First-in-class small inhibitors for treatment of a range of neurodegenerative diseases by safely counteracting glutamate excitotoxicity.

  • Board Member

    2022

  • Board Member

    2022

    Fibrocor utilizes its proprietary drug discovery engine to develop new medicines for individuals with fibrotic diseases.

  • Board Member

    2021

  • Observer, former Chairman and Board Member

    2022

    T-reg targeted therapies for long-lasting autoimmune disease control

  • Managing Director and Vice President

    2021 - 2021

    Strategic corporate venture capital arm of Merck, with €300m of investable capital. I invest in innovation, being jointly responsible for all biotechnology investments (biotherapeutics and life sciences tools and consumables). I act as the Life Sciences Interface with Merck.

  • Executive Investment Director

    2020 - 2021

  • Investment Director Healthcare

    2017 - 2020

  • Board Observer

    2021 - 2021

    Riffyn’s pioneering cloud system, Riffyn Nexus, is a process data system that places R&D process flows at the center of heterogeneous and fragmented R&D environments, delivering 2X faster development cycles and 4X productivity gains to the world’s scientific R&D organizations. Its process-centric experiment design, data capture, and data analytics overcome the limitations of traditional scientific data systems — delivering results that are always ready for machine learning.

  • Board Observer

    2020 - 2021

    DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science. The company is pioneering an alternative to traditional DNA synthesis called enzymatic DNA synthesis, or EDS, making this technology accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX™ System.

  • Board Observer

    2019 - 2021

    Single cell genomics-based approaches to identify novel immuno-oncology targets

Relevant Websites